Top

Category: Pricing


Pricing, Regulations

Pharma CEOs may be subpoenaed as IRA dispute rumbles on

January 22, 2024

Via: Pharmaphorum

The independent Vermont lawmaker is calling on J&J’s Joaquin Duato and Merck’s Robert Davis to explain personally why their medicines generally cost much more in the US. The two CEOs refused to testify in front of the HELP committee last […]


Pricing, Regulations

FDA authorises Florida’s request to import cheaper prescription drugs from Canada

January 9, 2024

Via: PMLiVE

Prescription drug pricing has been an ongoing issue in the US, which is reportedly spending more than double the average amount spent by other OECD member countries on prescription medicines per capita. Florida’s Canadian Prescription Drug Importation Program, which will […]


Pricing, Regulations

FDA Gives Florida OK to Import Cheaper Drugs From Canada

January 5, 2024

Via: Drugs.com

The U.S. Food and Drug Administration on Friday gave the nod to a Florida plan to import drugs from Canada at much lower prices than in the United States. The approval could prove to be a major turning point for […]


Pricing, Regulations

Biden may order compulsory licensing in drug pricing move

December 7, 2023

Via: Pharmaphorum

The proposed framework for so-called ‘march-in rights’ on taxpayer-funded drugs and other inventions is the latest entry in the US federal government’s playbook to limit price increases for drugs, and will no doubt throw it once again into open contention […]


Pricing, Regulations

Biden Pick to Lead NIH Finally Has Her Day, but Still Gets Caught Up in Drug Price Debate

October 19, 2023

Via: Kaiser Health News

A Senate committee finally held a hearing Wednesday on President Joe Biden’s pick to lead the National Institutes of Health. But the panel’s chair, Sen. Bernie Sanders (I-Vt.), was focused on drug prices — an issue over which the NIH […]


Pricing, Regulations

5 Things to Know About the New Drug Pricing Negotiations

August 30, 2023

Via: Kaiser Health News

The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major turning point in a long-fought battle to control ever-rising drug prices for […]


Pricing, Regulations

EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing

August 1, 2023

Via: Biopharma Dive

The acquisition is a quiet end for EQRx, which was launched three years ago by biotech venture capitalist Alexis Borisy and quickly became one of the sector’s most closely watched startups. EQRx formed with an unusual mission to develop lower-cost […]


Pricing, Regulations

J&J joins pharma allies in challenging US drug pricing law

July 19, 2023

Via: Biopharma Dive

The U.S. has long been the most lucrative market for pharmaceutical makers, in part because there are no mechanisms such as price negotiations to control the cost of medicines. As a result, Americans pay more than three times as much […]


Pricing, Regulations

In address to Congress, Biden touts drug pricing law and pushes insulin cost caps

February 8, 2023

Via: Biopharma Dive

President Biden doubled down on efforts to rein in prescription drug prices during his State of the Union address on Tuesday and warned Republicans that he will fight any attempts to roll back his initiatives. Biden called on lawmakers to […]


Pricing, Regulations

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

January 17, 2023

Via: PMLiVE

The companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as ‘the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry’. Introduced in […]


Pricing, Regulations

California sues insulin producers and PBMs over pricing

January 13, 2023

Via: Pharmaphorum

The lawsuit also takes aim at the three largest pharmacy benefit managers (PBMs) in the US – CVS Caremark, Express Scripts, and OptumRx – which are accused of adopting a system of rebates that incentivise manufacturers to raise list prices […]


Pricing, Regulations

Alzheimer’s drug Leqembi to launch at discount to Aduhelm

January 9, 2023

Via: Pharmaphorum

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology. Eisai and […]


Pricing, Regulations

States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada

December 14, 2022

Via: Kaiser Health News

The Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs. Colorado on Dec. 5 became at least the fourth state to seek federal permission to use the strategy, […]


Pricing, Regulations

How eligible patient numbers affect price of rare disease drugs in France

December 7, 2022

Via: Pharmaphorum

Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. The HTA body, the CT (Commission de la Transparence – Transparency Commission), is charged with providing guidance […]


Pricing, Regulations

Provention prices type 1 diabetes drug Tzield at $194,000

November 21, 2022

Via: Pharmaphorum

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the […]


Industry, Pricing, Regulations, Vaccines

Pfizer plans considerable 2023 Comirnaty markup

October 24, 2022

Via: Pharmaphorum

For over two years now, the US government has been running its public vaccination campaign – the largest in American history – and has purchased all of the Covid vaccines administered in the States, including over 500 million doses from […]


Pricing, Regulations

Amylyx ALS drug draws criticism over $158,000 price tag

October 3, 2022

Via: Pharmaphorum

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 […]


Pricing, Regulations

Pharma prepares to continue fight as drug pricing bill passes House

August 15, 2022

Via: Biopharma Dive

The pharmaceutical industry is gearing up to minimize the effect of major drug legislation passed by Congress on Friday, the first time in many years lawmakers have overcome the drug lobby’s opposition to limits on their pricing power. On Friday, […]


Pricing, Regulations

Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations

July 25, 2022

Via: Kaiser Health News

A snappy political advertisement from the conservative advocacy group American Commitment bluntly charges Sen. Joe Manchin (D-W.Va.) with supporting a legislative plan that would drain “billions in funds” from Medicare. Specifically, the ad claims that Manchin and AARP, the well-known advocacy group for people […]


Industry, Pharma, Pricing, Regulations

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe

July 22, 2022

Via: Pharmaphorum

The CMA delivered a preliminary judgment in the case last year which concluded that Pfizer and Flynn abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to […]